AKT1 and neoplasm: AutoDock Vina predicted that R7 selectively binds the Akt active binding domain (PDB codes: 3QKL, complexed with the inhibitor, N-{(2S)-3-[(3S)-8',9'-dihydro-1H,3'H-spiro [piperidine-3,7'-pyrano [3,2-e] indazol]-1-yl]-2-hydroxypropyl}-N-(2-ethoxyethyl)-2,6-dimethylbenzenesulfonamide, SMR) among 200 potential targets closely related to pathological tumor processes from the TTD (Therapeutic Target Database) and PDTD (Potential Drug Target Database), the top 10 lowest predicted binding energies (in kcal/mol) of R7 and potential targets from TTD were listed in Supplementary Table 2.